Dr. Devitt on circulating tumor cells in bladder cancer

Video

Michael Devitt, MD, a hematologist/oncologist and assistant professor at the University of Virginia Medical Center, discusses whether circulating tumors cells are ready for primetime as a diagnostic/prognostic biomarker in urothelial carcinoma.

Genomic testing has becoming increasingly critical in bladder cancer, as the FDAapproves novel targeted agents specifically for patients with certain genetic alterations. For example, erdafitinib (Balversa) is approved by the FDA for the treatment of patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations.

Related Videos
3d rendered illustration of bladder cancer | Image Credit: © SciePro - stock.adobe.com
Dr. Joshua Meeks in an interview with Urology Times
Alexander I. Sankin, MD, and Ahmed A. Aboumohamed, MD, answer questions during a video interview
A panel of 5 experts on bladder cancer
A panel of 5 experts on bladder cancer
A panel of 5 experts on bladder cancer
A panel of 5 experts on bladder cancer
Daniel P. Petrylak, MD, answers a question during a video interview
Related Content
© 2024 MJH Life Sciences

All rights reserved.